DexCom (NASDAQ:DXCM) Lifted to Buy at StockNews.com

StockNews.com upgraded shares of DexCom (NASDAQ:DXCM) from a hold rating to a buy rating in a research report released on Wednesday morning.

Other analysts have also recently issued reports about the company. UBS Group raised their price target on DexCom from $153.00 to $163.00 and gave the company a buy rating in a report on Wednesday, April 10th. Canaccord Genuity Group raised their price target on DexCom from $144.00 to $145.00 and gave the company a buy rating in a report on Friday, April 26th. Citigroup raised their price target on DexCom from $148.00 to $161.00 and gave the company a buy rating in a report on Wednesday, April 3rd. Raymond James raised their price target on DexCom from $151.00 to $160.00 and gave the company a strong-buy rating in a report on Friday, April 26th. Finally, Royal Bank of Canada began coverage on DexCom in a research note on Tuesday, March 12th. They issued an outperform rating and a $165.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $141.67.

DexCom Trading Down 1.2 %

DXCM opened at $125.88 on Wednesday. DexCom has a one year low of $74.75 and a one year high of $142.00. The business’s 50-day simple moving average is $131.68 and its 200-day simple moving average is $119.57. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The company has a market cap of $50.06 billion, a P/E ratio of 81.21, a PEG ratio of 2.14 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. As a group, equities research analysts expect that DexCom will post 1.77 EPS for the current fiscal year.

Insider Buying and Selling

In other DexCom news, CFO Jereme M. Sylvain sold 3,363 shares of DexCom stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the transaction, the chief financial officer now owns 71,142 shares in the company, valued at approximately $8,304,405.66. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the sale, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the transaction, the chief financial officer now owns 71,142 shares in the company, valued at approximately $8,304,405.66. The disclosure for this sale can be found here. Over the last quarter, insiders sold 189,375 shares of company stock valued at $25,530,859. Insiders own 0.41% of the company’s stock.

Institutional Investors Weigh In On DexCom

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Capital Research Global Investors raised its stake in DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after acquiring an additional 2,695,296 shares during the period. Sands Capital Management LLC grew its position in DexCom by 10.2% in the 4th quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after purchasing an additional 1,398,136 shares during the last quarter. Capital World Investors grew its position in DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after purchasing an additional 5,256,092 shares during the last quarter. Artisan Partners Limited Partnership grew its position in DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after purchasing an additional 3,672,471 shares during the last quarter. Finally, Blair William & Co. IL grew its position in DexCom by 1.7% in the 3rd quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock worth $420,517,000 after purchasing an additional 73,654 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.